CJC-1295 research guide for Coppet. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
CJC-1295 won't be found on pharmacy shelves in Coppet or anywhere else for that matter — it's a research compound available through a dedicated online market. This matters because CJC-1295 quality differs enormously across the market — from pharmaceutical-grade 99%+ purity to material with significant impurity issues — and the vendor is the entire quality system. The core quality markers for CJC-1295 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. The sections below cover what Coppet researchers need to know about finding, evaluating, and storing CJC-1295 for research purposes.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Coppet researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Evaluating CJC-1295 vendors requires starting from the COA: request the batch-specific certificate before placing an order, not after. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone provides no identity confirmation. Strong quality indicators beyond COA quality: established track record of at least two years, knowledgeable support capable of explaining COA data, and cold chain packaging that protects product integrity. For Coppet researchers making a first CJC-1295 purchase: verify the vendor against this framework, order conservatively at first, and verify batch traceability on arrival before use.
Order CJC-1295 — ships to Coppet
COA-verified · International tracking · Research grade
CJC-1295 is sold for research purposes only and is not approved for human consumption by the FDA or equivalent agencies worldwide — all information here is educational. Proper handling of CJC-1295 requires careful sterile procedure — prep pad-cleaned septum, single-use needles, uncontaminated workspace — and consistent cold chain handling. Bacterial endotoxin contamination is the primary safety concern unique to this class of compound — verify endotoxin testing is included in the batch-specific COA before any injectable research application. The research literature on CJC-1295 should be studied thoroughly before planning any study — study methodologies, dosing, and endpoints vary significantly and results do not always generalise across models.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
